Koate®-DVI (Antihemophilic Factor [Human])
Antihemophilic factor is a concentrate containing factors VIII and IX — clotting factors that
are used for treatment of persons with hemophilia. Hemophilia is a genetic disorder characterized
by the deficiency or absence of one of the proteins (or factors) in blood plasma that is responsible
for clotting. Low levels of one of these plasma proteins result in bleeding and difficulty clotting
in the affected individual. The most common deficiencies of clotting proteins are factor VIII and
factor IX. A doctor or healthcare provider prescribes antihemophilic therapies.
Please note: Country-specific regulatory requirements limit the information we can provide about our products. In addition,
approved indications (uses), product labels, and packaging for a prescription drug may differ between
countries. Please refer to the prescribing information provided for your country of residence.
Koate®-DVI (Antihemophilic Factor [Human]) reaches patients around the world, including in:
Antithrombin III (AT-III) is a blood protein that inhibits or stops the clotting factors
in blood. Approximately 75% of the body's plasma coagulation inhibitory activity is derived
from AT-III. AT-III deficiency is a rare inherited or spontaneously occurring condition
that affects one in every 2,000 to 5,000 males and females worldwide. Individuals with
the condition lack the AT-III protein and spontaneous clotting can occur as a result of
normal, daily activity. A doctor or healthcare provider prescribes Antithrombin III.
Please note: Country-specific regulatory requirements limit the information we can provide about our products. In addition,
approved indications (uses), product labels, and packaging for a prescription drug may differ between
countries. Please refer to the prescribing information provided for your country of residence.
Thrombate III®, Antithrombin III (Human) reaches patients around the world, including in:
Important Safety Information
Thrombate III therapy has demonstrated a low occurrence of side effects. In clinical studies with Thrombate III, the most common side effects were dizziness, chest tightness, nausea, and a foul taste in the mouth. As with all plasma-derived therapeutics, the potential to transmit infectious agents, such as viruses, cannot be totally eliminated. Individuals who receive infusions of blood or blood plasma may develop signs and/or symptoms of some viral infections, particularly hepatitis C.
Please see full Prescribing Information for Thrombate III.
|